Breaking: FDA approves twice-a-year HIV prevention shot

Lenacapavir, to be sold as Yeztugo, has potential to bring AIDS pandemic to heel but faces Trump-era obstacles.

Log In    Subscribe BREAKING NEWS   HIV protection with just two shots a year: FDA approves Gilead drug By Jason Mast and Ed Silverman Gilead The Food and Drug Administration approved Wednesday a powerful new drug that provides nearly complete protection against HIV infection with just a single administration every six months.   The injection, known chemically as lenacapavir and to be marketed as Yeztugo, has been hailed as the closest thing the field has ever had to a vaccine — a groundbreaking intervention that, if rolled out properly, could bring a 45-year-old pandemic to heel.  READ MORE Sign up for The Readout Your morning rundown of the science, politics, and money driving biotech today. Learn more. In Case You Missed It Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access? By Ed Silverman Rollout of 'miracle' HIV prevention drug is threatened by Trump cuts to global AIDS relief program By Ed Silverman and Jason Mast HIV prevention was making great strides. Then Trump's budget axe fell By Jason Mast CDC workers fired from prominent STI, hepatitis labs are rehired By Helen Branswell Get your first 3 months for $30 Unlock access to STAT's award-winning journalism, premium data tools, and must-read, subscriber-only newsletters. Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us